PharmaEssentia Corp’s (藥華醫藥) new drug for treating a blood disorder is forecast to generate revenue of up to 800 million euros (US$1 billion) a year in Europe, the firm’s European partner AOP Orphan Pharmaceuticals AG said.
The forecast figure is higher than PharmaEssentia’s own estimates of US$500 million, a company official said yesterday.
The P1101 (AOP2014) drug is designed to treat polycythemia vera, a disorder in which the bone marrow makes too many red blood cells.
The new drug, currently under phase-three clinical trials in the US and Europe, is expected to hit the markets between the end of next year and early 2016, said the official, who declined to be named.
PharmaEssentia licensed the drug to AOP in 2009, granting the latter exclusive rights to sell it in Europe. The Austrian firm expects the new drug would reach its peak sales five years after its launch.
Under the terms of their partnership, PharmaEssentia will book a milestone payment from AOP when the drug is approved for sale in Europe, in addition to royalties of about 20 percent of its sales and manufacturing fees for the drug.
The two companies maintain exclusive rights to sell the drug for 10 years after its launch in the US and seven years in Europe because P1101 is considered an orphan drug, one developed to treat a rare medical disorder, the official said.
However, PharmaEssentia will continue to report losses this year because it will book total expenses of NT$900 million (US$29.95 million), mainly from high research and development expenses of about NT$600 million, the official said.
“We are conducting three phase- three studies and many small trials at the same time this year,” she said.
The company posted a revenue of NT$75.97 million last year, up 1.67 times from NT$28.47 million the previous year. However, with total expenses reaching about NT$600 million, including NT$500 million for research and development, the company recorded a loss of NT$600 million or NT$3.2 per share, she said.
The company expects sales to rise by more than US$2 million this year as it ships more P1101 to AOP to test whether the drug can be used to treat other symptoms, the official said, adding that the company would conduct more experiments on a contract basis for other firms.
PharmaEssentia shares rose 2.3 percent to NT$155 yesterday, outperforming the over-the-counter index, which fell 1.6 percent.
Merida Industry Co (美利達) has seen signs of recovery in the US and European markets this year, as customers are gradually depleting their inventories, the bicycle maker told shareholders yesterday. Given robust growth in new orders at its Taiwanese factory, coupled with its subsidiaries’ improving performance, Merida said it remains confident about the bicycle market’s prospects and expects steady growth in its core business this year. CAUTION ON CHINA However, the company must handle the Chinese market with great caution, as sales of road bikes there have declined significantly, affecting its revenue and profitability, Merida said in a statement, adding that it would
Greek tourism student Katerina quit within a month of starting work at a five-star hotel in Halkidiki, one of the country’s top destinations, because she said conditions were so dire. Beyond the bad pay, the 22-year-old said that her working and living conditions were “miserable and unacceptable.” Millions holiday in Greece every year, but its vital tourism industry is finding it harder and harder to recruit Greeks to look after them. “I was asked to work in any department of the hotel where there was a need, from service to cleaning,” said Katerina, a tourism and marketing student, who would
i Gasoline and diesel prices at fuel stations are this week to rise NT$0.1 per liter, as tensions in the Middle East pushed crude oil prices higher last week, CPC Corp, Taiwan (台灣中油) and Formosa Petrochemical Corp (台塑石化) said yesterday. International crude oil prices last week rose for the third consecutive week due to an escalating conflict between Israel and Iran, as the market is concerned that the situation in the Middle East might affect crude oil supply, CPC and Formosa said in separate statements. Front-month Brent crude oil futures — the international oil benchmark — rose 3.75 percent to settle at US$77.01
RISING: Strong exports, and life insurance companies’ efforts to manage currency risks indicates the NT dollar would eventually pass the 29 level, an expert said The New Taiwan dollar yesterday rallied to its strongest in three years amid inflows to the nation’s stock market and broad-based weakness in the US dollar. Exporter sales of the US currency and a repatriation of funds from local asset managers also played a role, said two traders, who asked not to be identified as they were not authorized to speak publicly. State-owned banks were seen buying the greenback yesterday, but only at a moderate scale, the traders said. The local currency gained 0.77 percent, outperforming almost all of its Asian peers, to close at NT$29.165 per US dollar in Taipei trading yesterday. The
RSS